- CPHI’s report shows a surge in AI involvement in drug development, with over 50% of drugs anticipated to incorporate AI by 2030.
- Venture capitalists view ‘pharmaceutical AI companies’ as a more appealing investment than ‘late-stage’ and ‘early-stage’ biotech firms.
- AI’s potential applications include improvement in clinical trial designs, manufacturing processes, and base regulatory submissions, while also reducing costs.
Menu
